iX Biopharma Ltd. announced that on May, 29 2026 it allotted and issued 69,620 new ordinary shares pursuant to the exercise of warrants at an exercise price of 0.06 Singapore dollars per share, increasing its issued share capital to 1,057,006,585 shares from 1,056,936,965 shares.

The new shares will rank pari passu with existing shares and are expected to commence trading on the Singapore Exchange on or around Jun, 3 2026.

Following this exercise, 20,829,521 warrants—representing 36.22% of the warrants previously issued—have been exercised, leaving 36,679,958 warrants outstanding. These remaining warrants carry an exercise price of 0.06 Singapore dollars and will expire on Jul, 18 2026.